Efficacy of intravenous flurbiprofen axetil with epidural analgesia for post-cesarean section analgesia: a multi-center, prospective, randomized, blinded trial

Ling‐Yu Wang, Zurong Hu, Chunyuan Zhang, Zai-Shen Dai, Baoyi Han, Wei Zeng, Hong-Tao Hu, Xingrong Song, Ying‐Jun SheResearch 2021 · DOI

Introduction

Managing pain after a cesarean section is a complex clinical challenge. Patients typically experience two distinct types of pain: sharp, localized "stinging" at the surgical incision site and deep, visceral "dull" aching from uterine contractions as the organ shrinks back to its pre-pregnancy size. While patient-controlled epidural analgesia (PCEA) is considered the gold standard for managing incision pain, it often fails to adequately address uterine contraction pain. This visceral pain is frequently triggered by breastfeeding and oxytocin infusions, which stimulate the production of prostaglandins.

This multi-center, prospective, randomized, blinded trial investigated whether adding intravenous flurbiprofen axetil—a targeted nonsteroidal anti-inflammatory drug (NSAID)—to a standard PCEA regimen could provide more comprehensive relief and improve recovery outcomes.

Methods and Study Design

The researchers conducted a large-scale trial involving 1,000 obstetric patients across four medical centers. Patients were classified as ASA physical status I or II and scheduled for elective cesarean delivery.

CONSORT flow diagram illustrating the recruitment, randomization, and follow-up of the 1,000 study participants.

Participants were randomized into two groups:

  1. Group EF (Experimental): Received standard PCEA (0.1% ropivacaine + morphine) plus 50mg of intravenous flurbiprofen axetil immediately after delivery and twice daily for 48 hours.
  2. Group E (Control): Received standard PCEA plus a saline placebo.

Flurbiprofen axetil was chosen for its unique delivery system—lipid microspheres—which allows the drug to concentrate in inflamed tissues, reducing vascular irritation and enhancing efficacy. By inhibiting COX-1 and COX-2 enzymes, the drug blocks the synthesis of prostaglandins, the primary biochemical drivers of uterine pain.

Key Results

Enhanced Pain Relief

The study found that the combination therapy provided superior analgesia across multiple metrics. From 12 to 48 hours post-surgery, patients in Group EF reported significantly lower Visual Analogue Scale (VAS) scores for both uterine contraction pain and incision pain compared to the control group ($P < 0.01$). Notably, the relief extended to incision pain during movement (sitting and walking), suggesting that the NSAID effectively addressed "breakthrough" pain that local anesthetics alone might miss.

Accelerated Recovery of Gastrointestinal Function

One of the most striking findings was the impact on gastrointestinal (GI) recovery. The time to first "exhaust" (passage of flatus), a standard proxy for the return of bowel function, was nearly 40% faster in the flurbiprofen group (15 ± 6 hours vs. 25 ± 12 hours in the control group). This improvement is likely due to better pain control allowing for earlier mobilization; walking and light activity naturally stimulate gut motility.

Patient Satisfaction and Safety

Patient satisfaction scores were significantly higher in Group EF (3.2 vs. 2.9 on a 4-point scale). Furthermore, the incidence of constipation was lower in the flurbiprofen group ($P = 0.03$), while other common side effects like nausea, vomiting, and itching remained similar between the two groups. This suggests that the multimodal approach does not increase the side-effect burden while providing better clinical outcomes.

Discussion and Conclusion

The results of this trial underscore the importance of a multimodal approach to post-cesarean analgesia. By targeting the biochemical source of uterine pain—prostaglandin production—flurbiprofen axetil fills a critical gap left by epidural analgesia.

The study demonstrates that the benefits of effective pain management extend beyond comfort. Faster GI recovery and higher satisfaction scores indicate a higher quality of overall recovery, which is vital for new mothers who need to care for their newborns. While the study used a fixed 50mg dose, future research could explore dose optimization and the long-term psychological benefits of improved acute pain management, such as reduced rates of postpartum depression.

In conclusion, the combination of intravenous flurbiprofen axetil with PCEA offers a more effective and satisfying analgesic strategy for patients undergoing cesarean section, facilitating a faster return to normal function.

Summary updated

Abstract

Abstract BackgroundEpidural analgesia provided satisfactory analgesic effects of incision pain after cesarean section. However, uterine contraction pain is also a common complication that cannot be relieved despite adequate levels of sensory blockade by epidural analgesia. This study evaluates the effect of flurbiprofen axetil with patient-controlled epidural analgesia on incision pain and uterine contraction pain after cesarean section.MethodsA multi-center, prospective, randomized, blinded trial was performed. 1000 obstetric patients scheduled for cesarean delivery were randomized to receive epidural analgesia with intravenous flurbiprofen axetil (group EF) or placebo (group E) postoperatively. The primary outcomes were incision pain and uterine contraction pain score 48 hours after a cesarean section. Secondary outcomes were the PCEA attempts, the incidence of complication, satisfaction scores, and return of gastrointestinal (GI) function.ResultsBaseline characteristics were similar between groups. The VAS of uterine contraction pain was significantly lower in group EF than in group E from 12 hours to 48 hours after cesarean delivery (P &lt; 0.01). The VAS of incision pain at rest and on movement was lower in group EF than in group E from 12 hours to 48 hours after cesarean delivery. While sitting or walking, the VAS of incision pain was lower in group EF compared with that in group E. GI function recovered faster in group EF than that in group E (15 ± 6 vs. 25 ± 12, 95%CI 5.7 to 8.7, P &lt; 0.01). The satisfaction scores are higher in group EF than that in group E (3.2 ± 0.5 vs. 2.9 ± 0.5, 95%CI -0.36 to -0.11, P &lt; 0.01).ConclusionCombination flurbiprofen axetil with PCEA provides more effective analgesia for uterine contraction pain and incision pain after cesarean section, with a higher quality of recovery and better satisfaction scores.Trials RegistrationThis study was approved by the Institutional Review Board of Guangzhou Women and Children’s Medical Center (IRB2017062201) and written informed consent was obtained from his or her parents or legal guardians for each pediatric patient in the trial. The trial was registered before patient enrollment at chictr.org.cn (ChiCTR-IOR-17011956, Principal investigator: Ying-Jun She, Date of registration: 2017.07.12). Written informed consent was obtained from patients in the study.
BibTeX
@inproceedings{wang2021efficacy,
  author = {Ling‐Yu Wang and Zurong Hu and Chunyuan Zhang and Zai-Shen Dai and Baoyi Han and Wei Zeng and Hong-Tao Hu and Xingrong Song and Ying‐Jun She},
  title = {{Efficacy of intravenous flurbiprofen axetil with epidural analgesia for post-cesarean section analgesia: a multi-center, prospective, randomized, blinded trial}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-515788/v2},
}
Figure